Crispr Therapeutics AG

CRISPR Therapeutics AG is a biopharmaceutical company specializing in gene editing therapies using its proprietary CRISPR/Cas9 platform. This revolutionary technology enables precise alteration of genomic DNA sequences to develop transformative medicines for serious diseases. The company maintains a robust portfolio of programs targeting hemoglobinopathies like sickle cell disease and beta-thalassemia with ex vivo therapies such as CASGEVY, alongside CAR T cell therapies, in vivo editing for cardiovascular conditions including CTX310 and CTX460, and type 1 diabetes. Its pipeline also advances treatments for alpha-1 antitrypsin deficiency via novel SyNTase editing and oncology applications. CRISPR Therapeutics AG focuses on both ex vivo and in vivo modalities to address unmet needs in hematology, immunology, oncology, cardiovascular, and rare genetic disorders. Founded in 2013 and headquartered in Zug, Switzerland, with key operations in Boston, the company plays a pivotal role in advancing gene-based treatments toward clinical and commercial stages in the biotechnology sector.